To assess whether forward extension of both arms improves gait initiation in patients with PD, measured by faster coverage of the initial two meters of walking. Secondary objectives are to determine whether this change in performance can be measured…
ID
Source
Brief title
Condition
- Movement disorders (incl parkinsonism)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
gait velocity over the initial two meters and full six meters of walking after
starting as determined using (i) a stopwatch and distance markers or (ii) IMU
signals, comparing gait initiation with and without forward arm extension.
Secondary outcome
left and right step length as derived from IMU signals, compared between gait
initiation with and without arm extension. Correlation between the primary and
secondary outcome parameters and the MDS-UPDRS (Part III) motor score and item
gait (3.10), in particular. Correlation between the primary study parameters
and subjective assessment of changes in gait performance.
Background summary
Walking of patients suffering from Parkinson*s disease (PD) is characterized by
small steps, loss of arm swing and starting problems. Impaired function of the
Supplementary Motor Area (SMA), which is an important output target of
striato-thalamic projections, is argued to play a causal role in this
disturbance of both motor initiation and organization of multi-limb movements.
By applying forward arm extension as a cue for gait initiation, we hypothesize
that starting to walk will improve due to (i) facilitating SMA activity to fuel
the cyclic motor program of gait and (ii) a forward shift of the patient*s
axial center of gravity, stimulating the natural response of a forward foot
placement.
Study objective
To assess whether forward extension of both arms improves gait initiation in
patients with PD, measured by faster coverage of the initial two meters of
walking. Secondary objectives are to determine whether this change in
performance can be measured accurately using only a stopwatch and distance
markers and to what extent the use of inertial measurement units (IMUs) adds
essential information. Moreover, the relationship between these parameters and
the patient*s subjective assessment of gait initiation will additionally be
assessed.
Study design
Observational study
During the tasks gait initiation performance will be measured using IMUs
(integrating accelerometers, gyroscopes and magnetometers in a matchbox-like
container) on both shanks and both thighs and a stopwatch and distance markers.
The IMUs can be used to determine bilateral step size and gait velocity
objectively and accurately. Gait will be assessed over a distance of six meters
with timing passage of the initial two meters distance and the full six meters.
For future clinical application, we will additionally investigate whether
measurement of gait velocity using only a stopwatch and distance markers is
sufficiently accurate, as well. After measurement preparation and task
instruction, the participant has to perform the following tasks:
1. 6 meter walk test (repeated 3 times, initiated at a verbal signal of the
examiner) without arm extension
2. 6 meter walk test (repeated 3 times, initiated at a verbal signal of the
examiner) with simultaneous arm extension at gait initiation
The six gait trials will be executed semi-randomly; the first trial will always
be gait initiation without arm extension. After executing all trials patients
will be asked about their subjective assessment of their performance using a
questionnaire.
Other parameters of interest (Hoehn & Yahr stage, MDS-UPDRS part III score,
side of symptom dominance) will be collected from the patient*s file.
The study will consist of a pilot study and a cross-sectional study in which
gait initiation performance with and without arm extension will be compared in
PD patients.
Intervention
Forward arm extension at gait initiation
Study burden and risks
There are no risks or benefits, and the burden is limited to the time invested
in the test (approximately 30 minutes, with breaks if necessary).
Hanzeplein 1
Groningen 9713 GZ
NL
Hanzeplein 1
Groningen 9713 GZ
NL
Listed location countries
Age
Inclusion criteria
Healthy individuals:
- Perceived healthy
- Age >= 18 years
- Written informed consent
PD Patients:
- able to walk (Hoehn & Yahr scale: Stage 2-3)
- trouble initiating gait (as reported in the medical file)
- PD diagnosis according to the UK Parkinson*s Disease Society Brain Bank criteria (A.J. Hughes, 1992)
- Age < 80 (to limit the presence of general age-related deficits)
- Written informed consent
Exclusion criteria
All participants
- (other) neurological or motor disorder (for patients: other than PD)
- Use of medication influencing movement (for patients: other than for PD)
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL62280.042.17 |